Stopping Ozanimod: What People with MS Need to Know

Credibility

Interest

Key Takeaway

Most people did not have new or worse MS attacks after stopping ozanimod, and there was no clear sign of a rebound effect.

What They Found

Researchers looked at people who stopped taking ozanimod, a medicine for relapsing MS, to see if their disease came back worse than before. Out of 1,679 people who had follow-up after stopping, 55 (about 3%) had a confirmed relapse — that means a return or worsening of symptoms lasting long enough to be counted. Almost all of those who relapsed were not taking any other MS medicine at the time of their relapse. Most relapses caused small to moderate increases in disability and most people got better; 76% fully recovered and 20% partially recovered. The study did not find cases that looked like a severe “rebound,” where disease comes back much worse than expected after stopping treatment.

Who Should Care and Why

People with relapsing MS who are thinking about stopping ozanimod or switching medicines should care because this study suggests stopping ozanimod usually does not cause a dramatic return of disease. Caregivers and family members can use this information to plan follow-up and watch for symptoms in the weeks after stopping treatment, much like checking a house more often after returning from a trip. Healthcare providers can use these results when discussing risks and benefits of stopping ozanimod, and when planning how soon to start another therapy if needed. Patients who are not starting a new MS medicine right away should be aware that most relapses happened without another treatment in place, so timely planning matters. People with higher disability or other health issues may still need closer monitoring, because the study shows most but not all recover fully.

Important Considerations

This was an exploratory look at people who left a long trial, not a randomized experiment, so other factors could affect who relapsed. About 31% of people had only short follow-up (60 days or less), so some relapses might have been missed if they happened later. Because almost everyone who relapsed was not on another MS medicine, we can’t tell from this study whether switching quickly to a different drug would change the risk.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Progression

Article Topics:

discontinuationdisease‐modifying therapymultiple sclerosisozanimodreboundrelapse

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of clinical and translational neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News